{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:18:53Z","timestamp":1761920333808,"version":"3.37.3"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"SNF","award":["31003A_146286"],"award-info":[{"award-number":["31003A_146286"]}]},{"name":"Initial Training Network grant \u201cADVance\u201d"},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e4t Z\u00fcrich (CH)"},{"DOI":"10.13039\/501100004784","name":"Novartis Stiftung\u00a0f\u00fcr\u00a0Medizinisch-Biologische Forschung","doi-asserted-by":"publisher","award":["16C222"],"award-info":[{"award-number":["16C222"]}],"id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12985-017-0822-5","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T12:42:34Z","timestamp":1503060154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies"],"prefix":"10.1186","volume":"14","author":[{"given":"Martin","family":"Pacesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodinde","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Bieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin W.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs F.","family":"Greber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Hemmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"822_CR1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0031-1283287","volume":"32","author":"JP Lynch 3rd","year":"2011","unstructured":"Lynch JP 3rd, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med. 2011;32:494\u2013511.","journal-title":"Semin Respir Crit Care Med"},{"key":"822_CR2","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1128\/JVI.00491-11","volume":"85","author":"K Aoki","year":"2011","unstructured":"Aoki K, Benko M, Davison AJ, Echavarria M, Erdman DD, Harrach B, Kajon AE, Schnurr D, Wadell G, Members of the Adenovirus Research C. Toward an integrated human adenovirus designation system that utilizes molecular and serological data and serves both clinical and fundamental virology. J Virol. 2011;85:5703\u20134.","journal-title":"J Virol"},{"key":"822_CR3","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/JVI.00354-11","volume":"85","author":"D Seto","year":"2011","unstructured":"Seto D, Chodosh J, Brister JR, Jones MS, Members of the Adenovirus Research C. Using the whole-genome sequence to characterize and name human adenoviruses. J Virol. 2011;85:5701\u20132.","journal-title":"J Virol"},{"key":"822_CR4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cmi.12031","volume":"15","author":"UF Greber","year":"2013","unstructured":"Greber UF, Arnberg N, Wadell G, Benko M, Kremer EJ. Adenoviruses - from pathogens to therapeutics: a report on the 10th International Adenovirus Meeting. Cell Microbiol. 2013;15:16\u201323.","journal-title":"Cell Microbiol"},{"key":"822_CR5","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1128\/JVI.02568-15","volume":"90","author":"UF Greber","year":"2016","unstructured":"Greber UF. Virus and host mechanics support membrane penetration and cell entry. J Virol. 2016;90:3802\u20135.","journal-title":"J Virol"},{"key":"822_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coviro.2012.12.004","volume":"3","author":"M Suomalainen","year":"2013","unstructured":"Suomalainen M, Greber UF. Uncoating of non-enveloped viruses. Curr Opin Virol. 2013;3:27\u201333.","journal-title":"Curr Opin Virol"},{"key":"822_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cmi.12053","volume":"15","author":"N Wolfrum","year":"2013","unstructured":"Wolfrum N, Greber UF. Adenovirus signalling in entry. Cell Microbiol. 2013;15:53\u201362.","journal-title":"Cell Microbiol"},{"key":"822_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2013.228","volume":"25","author":"E Lopez-Gordo","year":"2014","unstructured":"Lopez-Gordo E, Podgorski II, Downes N, Alemany R. Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther. 2014;25:285\u2013300.","journal-title":"Hum Gene Ther"},{"key":"822_CR9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cells4030277","volume":"4","author":"JW Flatt","year":"2015","unstructured":"Flatt JW, Greber UF. Misdelivery at the nuclear pore complex-stopping a virus dead in its tracks. Cell. 2015;4:277\u201396.","journal-title":"Cell"},{"key":"822_CR10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","volume":"25","author":"R Hendrickx","year":"2014","unstructured":"Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. Innate immunity to adenovirus. Hum Gene Ther. 2014;25:265\u201384.","journal-title":"Hum Gene Ther"},{"key":"822_CR11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.chom.2013.09.004","volume":"14","author":"IH Wang","year":"2013","unstructured":"Wang IH, Suomalainen M, Andriasyan V, Kilcher S, Mercer J, Neef A, Luedtke NW, Greber UF. Tracking viral genomes in host cells at single-molecule resolution. Cell Host Microbe. 2013;14:468\u201380.","journal-title":"Cell Host Microbe"},{"key":"822_CR12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425247.2014.874414","volume":"11","author":"D Kasala","year":"2014","unstructured":"Kasala D, Choi JW, Kim SW, Yun CO. Utilizing adenovirus vectors for gene delivery in cancer. Expert Opin Drug Deliv. 2014;11:379\u201392.","journal-title":"Expert Opin Drug Deliv"},{"key":"822_CR13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/156652311796150363","volume":"11","author":"R Khare","year":"2011","unstructured":"Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther. 2011;11:241\u201358.","journal-title":"Curr Gene Ther"},{"key":"822_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-800276-6.00002-4","volume-title":"Adenoviral vectors for gene therapy","author":"S Luisoni","year":"2016","unstructured":"Luisoni S, Greber UF. Biology of adenovirus cell entry \u2013 receptors, pathways, mechanisms. In: Curiel DT, editor. Adenoviral vectors for gene therapy. London: Academic Press, Elsevier; 2016. p. 27\u201358."},{"key":"822_CR15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.gt.3302058","volume":"10","author":"H Nagel","year":"2003","unstructured":"Nagel H, Maag S, Tassis A, Nestle FO, Greber UF, Hemmi S. The alphavbeta5 integrin of hematopoietic and nonhematopoietic cells is a transduction receptor of RGD-4C fiber-modified adenoviruses. Gene Ther. 2003;10:1643\u201353.","journal-title":"Gene Ther"},{"key":"822_CR16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/infdis\/171.5.1090","volume":"171","author":"P Flomenberg","year":"1995","unstructured":"Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis. 1995;171:1090\u20136.","journal-title":"J Infect Dis"},{"key":"822_CR17","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1128\/JVI.70.9.6314-6322.1996","volume":"70","author":"P Flomenberg","year":"1996","unstructured":"Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon. J Virol. 1996;70:6314\u201322.","journal-title":"J Virol"},{"key":"822_CR18","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/JVI.62.7.2321-2328.1988","volume":"62","author":"C Wohlfart","year":"1988","unstructured":"Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol. 1988;62:2321\u20138.","journal-title":"J Virol"},{"key":"822_CR19","first-page":"1732","volume-title":"Fields virology","author":"WS Wold","year":"2013","unstructured":"Wold WS, Ison MG. Adenoviruses. In: Knipe DM, Howley PM, editors. Fields virology, vol. 2. Philadelphia, New York: Wolters Kluwer, Lippincott Williams & Wilkins; 2013. p. 1732\u201367."},{"key":"822_CR20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1128\/JVI.02392-08","volume":"83","author":"CT Garnett","year":"2009","unstructured":"Garnett CT, Talekar G, Mahr JA, Huang W, Zhang Y, Ornelles DA, Gooding LR. Latent species C adenoviruses in human tonsil tissues. J Virol. 2009;83:2417\u201328.","journal-title":"J Virol"},{"key":"822_CR21","doi-asserted-by":"crossref","first-page":"e1005415","DOI":"10.1371\/journal.ppat.1005415","volume":"12","author":"Y Zheng","year":"2016","unstructured":"Zheng Y, Stamminger T, Hearing P. E2F\/Rb family proteins mediate interferon induced repression of adenovirus immediate early transcription to promote persistent viral infection. PLoS Pathog. 2016;12:e1005415.","journal-title":"PLoS Pathog"},{"key":"822_CR22","doi-asserted-by":"crossref","first-page":"381 e381","DOI":"10.1016\/j.cmi.2015.12.013","volume":"22","author":"K Kosulin","year":"2016","unstructured":"Kosulin K, Geiger E, Vecsei A, Huber WD, Rauch M, Brenner E, Wrba F, Hammer K, Innerhofer A, Potschger U, et al. Persistence and reactivation of human adenoviruses in the gastrointestinal tract. Clin Microbiol Infect. 2016;22:381 e381\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"822_CR23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","volume":"27","author":"T Lion","year":"2014","unstructured":"Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27:441\u201362.","journal-title":"Clin Microbiol Rev"},{"key":"822_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coviro.2011.12.008","volume":"2","author":"GR Nemerow","year":"2012","unstructured":"Nemerow GR, Stewart PL, Reddy VS. Structure of human adenovirus. Curr Opin Virol. 2012;2:115\u201321.","journal-title":"Curr Opin Virol"},{"key":"822_CR25","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JVI.72.3.2388-2397.1998","volume":"72","author":"H Gahery-Segard","year":"1998","unstructured":"Gahery-Segard H, Farace F, Godfrin D, Gaston J, Lengagne R, Tursz T, Boulanger P, Guillet JG. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol. 1998;72:2388\u201397.","journal-title":"J Virol"},{"key":"822_CR26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1525-0016(03)00067-4","volume":"7","author":"SS Hong","year":"2003","unstructured":"Hong SS, Magnusson MK, Henning P, Lindholm L, Boulanger PA. Adenovirus stripping: a versatile method to generate adenovirus vectors with new cell target specificity. Mol Ther. 2003;7:692\u20139.","journal-title":"Mol Ther"},{"key":"822_CR27","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/JVI.02023-06","volume":"81","author":"SL Pichla-Gollon","year":"2007","unstructured":"Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao GP, Wilson JM, Ertl HC, Burnett RM, Bergelson JM. Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol. 2007;81:1680\u20139.","journal-title":"J Virol"},{"issue":"Pt 6","key":"822_CR28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1099\/0022-1317-73-6-1429","volume":"73","author":"CI Toogood","year":"1992","unstructured":"Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol. 1992;73(Pt 6):1429\u201335.","journal-title":"J Gen Virol"},{"key":"822_CR29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","volume":"86","author":"RR Bradley","year":"2012","unstructured":"Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol. 2012;86:625\u20139.","journal-title":"J Virol"},{"key":"822_CR30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.00866-09","volume":"84","author":"C Cheng","year":"2010","unstructured":"Cheng C, Gall JG, Nason M, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR, et al. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol. 2010;84:630\u20138.","journal-title":"J Virol"},{"key":"822_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.virol.2004.12.029","volume":"333","author":"S Roy","year":"2005","unstructured":"Roy S, Clawson DS, Calcedo R, Lebherz C, Sanmiguel J, Wu D, Wilson JM. Use of chimeric adenoviral vectors to assess capsid neutralization determinants. Virology. 2005;333:207\u201314.","journal-title":"Virology"},{"key":"822_CR32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","volume":"441","author":"DM Roberts","year":"2006","unstructured":"Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441:239\u201343.","journal-title":"Nature"},{"key":"822_CR33","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","volume":"174","author":"SM Sumida","year":"2005","unstructured":"Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174:7179\u201385.","journal-title":"J Immunol"},{"key":"822_CR34","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1128\/JVI.70.3.1836-1844.1996","volume":"70","author":"L Crawford-Miksza","year":"1996","unstructured":"Crawford-Miksza L, Schnurr DP. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol. 1996;70:1836\u201344.","journal-title":"J Virol"},{"key":"822_CR35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/mthe.1999.0001","volume":"1","author":"JJ Rux","year":"2000","unstructured":"Rux JJ, Burnett RM. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther. 2000;1:18\u201330.","journal-title":"Mol Ther"},{"key":"822_CR36","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1128\/JVI.77.17.9553-9566.2003","volume":"77","author":"JJ Rux","year":"2003","unstructured":"Rux JJ, Kuser PR, Burnett RM. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol. 2003;77:9553\u201366.","journal-title":"J Virol"},{"key":"822_CR37","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/JCM.37.6.1839-1845.1999","volume":"37","author":"S Takeuchi","year":"1999","unstructured":"Takeuchi S, Itoh N, Uchio E, Aoki K, Ohno S. Serotyping of adenoviruses on conjunctival scrapings by PCR and sequence analysis. J Clin Microbiol. 1999;37:1839\u201345.","journal-title":"J Clin Microbiol"},{"key":"822_CR38","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1128\/JVI.72.12.10260-10264.1998","volume":"72","author":"JG Gall","year":"1998","unstructured":"Gall JG, Crystal RG, Falck-Pedersen E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol. 1998;72:10260\u20134.","journal-title":"J Virol"},{"key":"822_CR39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.virusres.2011.06.017","volume":"160","author":"X Tian","year":"2011","unstructured":"Tian X, Su X, Li H, Li X, Zhou Z, Liu W, Zhou R. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res. 2011;160:214\u201320.","journal-title":"Virus Res"},{"key":"822_CR40","doi-asserted-by":"crossref","first-page":"12775","DOI":"10.1128\/JVI.76.24.12775-12782.2002","volume":"76","author":"H Wu","year":"2002","unstructured":"Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol. 2002;76:12775\u201382.","journal-title":"J Virol"},{"key":"822_CR41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/10430340252769824","volume":"13","author":"R Youil","year":"2002","unstructured":"Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, Casimiro D. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther. 2002;13:311\u201320.","journal-title":"Hum Gene Ther"},{"key":"822_CR42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbrc.2012.03.125","volume":"421","author":"B Yu","year":"2012","unstructured":"Yu B, Wang C, Dong J, Zhang M, Zhang H, Wu J, Wu Y, Kong W, Yu X. Chimeric hexon HVRs protein reflects partial function of adenovirus. Biochem Biophys Res Commun. 2012;421:170\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"822_CR43","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1016\/j.vaccine.2009.06.041","volume":"27","author":"X Yuan","year":"2009","unstructured":"Yuan X, Qu Z, Wu X, Wang Y, Liu L, Wei F, Gao H, Shang L, Zhang H, Cui H, et al. Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. Vaccine. 2009;27:5103\u201310.","journal-title":"Vaccine"},{"key":"822_CR44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF01310543","volume":"87","author":"E Adam","year":"1986","unstructured":"Adam E, Lengyel A, Takacs M, Erdei J, Fachet J, Nasz I. Grouping of monoclonal antibodies to adenovirus hexons by their cross-reactivity. Arch Virol. 1986;87:61\u201371.","journal-title":"Arch Virol"},{"key":"822_CR45","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1128\/JCM.43.9.4426-4433.2005","volume":"43","author":"U Bauer","year":"2005","unstructured":"Bauer U, Flunker G, Bruss K, Kallwellis K, Liebermann H, Luettich T, Motz M, Seidel W. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J Clin Microbiol. 2005;43:4426\u201333.","journal-title":"J Clin Microbiol"},{"key":"822_CR46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4049\/jimmunol.116.1.19","volume":"116","author":"N Willcox","year":"1976","unstructured":"Willcox N, Mautner V. Antigenic determinants of adenovirus capsids. I. Measurement of antibody cross-reactivity. J Immunol. 1976;116:19\u201324.","journal-title":"J Immunol"},{"key":"822_CR47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4049\/jimmunol.116.1.25","volume":"116","author":"N Willcox","year":"1976","unstructured":"Willcox N, Mautner V. Antigenic determinants of adenovirus capsids. II. Homogeneity of hexons, and accessibility of their determinants, in the virion. J Immunol. 1976;116:25\u20139.","journal-title":"J Immunol"},{"key":"822_CR48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virusres.2011.05.023","volume":"160","author":"S Hemmi","year":"2011","unstructured":"Hemmi S, Vidovszky MZ, Ruminska J, Ramelli S, Decurtins W, Greber UF, Harrach B. Genomic and phylogenetic analyses of murine adenovirus 2. Virus Res. 2011;160:128\u201335.","journal-title":"Virus Res."},{"key":"822_CR49","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1128\/JVI.02281-08","volume":"83","author":"B Klempa","year":"2009","unstructured":"Klempa B, Kruger DH, Auste B, Stanko M, Krawczyk A, Nickel KF, Uberla K, Stang A. A novel cardiotropic murine adenovirus representing a distinct species of mastadenoviruses. J Virol. 2009;83:5749\u201359.","journal-title":"J Virol"},{"key":"822_CR50","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1128\/AAC.01311-07","volume":"52","author":"L Lenaerts","year":"2008","unstructured":"Lenaerts L, Kelchtermans H, Geboes L, Matthys P, Verbeken E, De Clercq E, Naesens L. Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. Antimicrob Agents Chemother. 2008;52:1462\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"822_CR51","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/JVI.02561-08","volume":"83","author":"M Robinson","year":"2009","unstructured":"Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, VanRoey M, Spindler KR, Jooss K. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J Virol. 2009;83:3450\u201362.","journal-title":"J Virol"},{"key":"822_CR52","volume-title":"Murine adenoviruses","author":"K Smith","year":"1999","unstructured":"Smith K, Spindler K. Murine adenoviruses. New York: John Wiley and Sons Ltd; 1999."},{"key":"822_CR53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.virol.2005.06.021","volume":"340","author":"JB Weinberg","year":"2005","unstructured":"Weinberg JB, Stempfle GS, Wilkinson JE, Younger JG, Spindler KR. Acute respiratory infection with mouse adenovirus type 1. Virology. 2005;340:245\u201354.","journal-title":"Virology"},{"key":"822_CR54","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1089\/hum.1998.9.16-2363","volume":"9","author":"S Hemmi","year":"1998","unstructured":"Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther. 1998;9:2363\u201373.","journal-title":"Hum Gene Ther"},{"key":"822_CR55","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.gt.3301940","volume":"10","author":"I Peter","year":"2003","unstructured":"Peter I, Graf C, Dummer R, Schaffner W, Greber UF, Hemmi S. A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Ther. 2003;10:530\u20139.","journal-title":"Gene Ther"},{"key":"822_CR56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(83)90012-0","volume":"33","author":"P Hearing","year":"1983","unstructured":"Hearing P, Shenk T. The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element. Cell. 1983;33:695\u2013703.","journal-title":"Cell"},{"key":"822_CR57","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01314287","volume":"91","author":"T Adrian","year":"1986","unstructured":"Adrian T, Wadell G, Hierholzer JC, Wigand R. DNA restriction analysis of adenovirus prototypes 1 to 41. Arch Virol. 1986;91:277\u201390.","journal-title":"Arch Virol"},{"key":"822_CR58","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1099\/vir.0.83142-0","volume":"88","author":"C Fleischli","year":"2007","unstructured":"Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF, Hemmi S. Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol. 2007;88:2925\u201334.","journal-title":"J Gen Virol"},{"key":"822_CR59","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1128\/JVI.78.22.12320-12332.2004","volume":"78","author":"R Varghese","year":"2004","unstructured":"Varghese R, Mikyas Y, Stewart PL, Ralston R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol. 2004;78:12320\u201332.","journal-title":"J Virol"},{"key":"822_CR60","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/mt.2010.169","volume":"18","author":"MA Hausl","year":"2010","unstructured":"Hausl MA, Zhang W, Muther N, Rauschhuber C, Franck HG, Merricks EP, Nichols TC, Kay MA, Ehrhardt A. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther. 2010;18:1896\u2013906.","journal-title":"Mol Ther"},{"key":"822_CR61","doi-asserted-by":"crossref","first-page":"10123","DOI":"10.1128\/JVI.01102-12","volume":"86","author":"A Yakimovich","year":"2012","unstructured":"Yakimovich A, Gumpert H, Burckhardt CJ, Lutschg VA, Jurgeit A, Sbalzarini IF, Greber UF. Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model. J Virol. 2012;86:10123\u201337.","journal-title":"J Virol"},{"key":"822_CR62","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","volume":"227","author":"UK Laemmli","year":"1970","unstructured":"Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680\u20135.","journal-title":"Nature"},{"key":"822_CR63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/JVI.75.1.480-489.2001","volume":"75","author":"C Ebbinghaus","year":"2001","unstructured":"Ebbinghaus C, Al-Jaibaji A, Operschall E, Schoffel A, Peter I, Greber UF, Hemmi S. Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter. J Virol. 2001;75:480\u20139.","journal-title":"J Virol"},{"key":"822_CR64","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1128\/JVI.00467-11","volume":"85","author":"HC Ma","year":"2011","unstructured":"Ma HC, Hearing P. Adenovirus structural protein IIIa is involved in the serotype specificity of viral DNA packaging. J Virol. 2011;85:7849\u201355.","journal-title":"J Virol"},{"key":"822_CR65","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/JVI.79.4.2604-2613.2005","volume":"79","author":"O Meier","year":"2005","unstructured":"Meier O, Gastaldelli M, Boucke K, Hemmi S, Greber UF. Early steps of clathrin-mediated endocytosis involved in phagosomal escape of Fcgamma receptor-targeted adenovirus. J Virol. 2005;79:2604\u201313.","journal-title":"J Virol"},{"key":"822_CR66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1099\/0022-1317-56-2-393","volume":"56","author":"WC Russell","year":"1981","unstructured":"Russell WC, Patel G, Precious B, Sharp I, Gardner PS. Monoclonal antibodies against adenovirus type 5: preparation and preliminary characterization. J Gen Virol. 1981;56:393\u2013408.","journal-title":"J Gen Virol"},{"key":"822_CR67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/cgt.2010.79","volume":"18","author":"O Hemminki","year":"2011","unstructured":"Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 2011;18:288\u201396.","journal-title":"Cancer Gene Ther"},{"key":"822_CR68","doi-asserted-by":"crossref","first-page":"13370","DOI":"10.1038\/srep13370","volume":"5","author":"Y Guan","year":"2015","unstructured":"Guan Y, Zhu Q, Huang D, Zhao S, Jan Lo L, Peng J. An equation to estimate the difference between theoretically predicted and SDS PAGE-displayed molecular weights for an acidic peptide. Sci Rep. 2015;5:13370.","journal-title":"Sci Rep"},{"key":"822_CR69","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/15287390701551324","volume":"70","author":"EK Park","year":"2007","unstructured":"Park EK, Mak SK, Kultz D, Hammock BD. Evaluation of cytotoxicity attributed to thimerosal on murine and human kidney cells. J Toxicol Environ Health A. 2007;70:2092\u20135.","journal-title":"J Toxicol Environ Health A"},{"key":"822_CR70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1099\/vir.0.82445-0","volume":"88","author":"V Sherwood","year":"2007","unstructured":"Sherwood V, Burgert HG, Chen YH, Sanghera S, Katafigiotis S, Randall RE, Connerton I, Mellits KH. Improved growth of enteric adenovirus type 40 in a modified cell line that can no longer respond to interferon stimulation. J Gen Virol. 2007;88:71\u20136.","journal-title":"J Gen Virol"},{"key":"822_CR71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1432-1033.1973.tb03100.x","volume":"39","author":"PA Boulanger","year":"1973","unstructured":"Boulanger PA, Puvion F. Large-scale preparation of soluble adenovirus hexon, penton and fiber antigens in highly purified form. Eur J Biochem. 1973;39:37\u201342.","journal-title":"Eur J Biochem"},{"key":"822_CR72","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00018-011-0740-4","volume":"68","author":"E Szolajska","year":"2011","unstructured":"Szolajska E, Chroboczek J. Faithful chaperones. Cell Mol Life Sci. 2011;68:3307\u201322.","journal-title":"Cell Mol Life Sci"},{"key":"822_CR73","doi-asserted-by":"crossref","first-page":"e103058","DOI":"10.1371\/journal.pone.0103058","volume":"9","author":"M Liu","year":"2014","unstructured":"Liu M, Tian X, Li X, Zhou Z, Li C, Zhou R. Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector. PLoS One. 2014;9:e103058.","journal-title":"PLoS One"},{"key":"822_CR74","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1128\/JVI.07076-11","volume":"86","author":"H Qiu","year":"2012","unstructured":"Qiu H, Li X, Tian X, Zhou Z, Xing K, Li H, Tang N, Liu W, Bai P, Zhou R. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions. J Virol. 2012;86:7964\u201375.","journal-title":"J Virol"},{"key":"822_CR75","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1128\/JVI.00473-13","volume":"87","author":"ND Myers","year":"2013","unstructured":"Myers ND, Skorohodova KV, Gounder AP, Smith JG. Directed evolution of mutator adenoviruses resistant to antibody neutralization. J Virol. 2013;87:6047\u201350.","journal-title":"J Virol"},{"key":"822_CR76","first-page":"7","volume":"3","author":"Chiron Mimotopes Pty. L","year":"1993","unstructured":"Chiron Mimotopes Pty. L. Determination of antibody binding parameters using biotinylated peptides. Pinnacles. 1993;3:7\u201311.","journal-title":"Pinnacles"},{"key":"822_CR77","doi-asserted-by":"crossref","first-page":"12635","DOI":"10.1128\/JVI.79.20.12635-12642.2005","volume":"79","author":"K Ebner","year":"2005","unstructured":"Ebner K, Pinsker W, Lion T. Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol. 2005;79:12635\u201342.","journal-title":"J Virol"},{"key":"822_CR78","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1128\/JVI.79.24.15265-15276.2005","volume":"79","author":"I Madisch","year":"2005","unstructured":"Madisch I, Harste G, Pommer H, Heim A. Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J Virol. 2005;79:15265\u201376.","journal-title":"J Virol"},{"key":"822_CR79","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1128\/JVI.00728-12","volume":"86","author":"WA McEwan","year":"2012","unstructured":"McEwan WA, Hauler F, Williams CR, Bidgood SR, Mallery DL, Crowther RA, James LC. Regulation of virus neutralization and the persistent fraction by TRIM21. J Virol. 2012;86:8482\u201391.","journal-title":"J Virol"},{"key":"822_CR80","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1128\/JVI.00557-08","volume":"82","author":"JG Smith","year":"2008","unstructured":"Smith JG, Cassany A, Gerace L, Ralston R, Nemerow GR. Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport. J Virol. 2008;82:6492\u2013500.","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-017-0822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T04:09:18Z","timestamp":1692936558000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-017-0822-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1186\/s12985-017-0822-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"article-number":"158"}}